Financial Data and Key Metrics Changes - Fourth quarter revenue increased by 12% to $269 million, and full year revenue increased by 14% to $912 million, primarily driven by growth at existing centers and new center additions [18][19] - Fourth quarter net income per diluted share increased from $3.51 to $4.66, while full year net income per diluted share increased from $3.09 to $4.89 [18] - Fourth quarter operating cash flow was $52 million, bringing the full year total to $117 million [19] Business Line Data and Key Metrics Changes - The Inspire V system demonstrated superiority over Inspire IV, with a 79.5% responder rate in the Singapore study compared to 66% in the STAR phase III pivotal trial [11] - CPT code 64568 was used for approximately 10,000 Inspire V procedures in 2025, providing a basis for professional reimbursement [9] Market Data and Key Metrics Changes - The company is revising its full year revenue outlook for 2026 to a range of $950 million to $1 billion, reflecting expected impacts from coding uncertainty and physician reimbursement rates [20] - The company anticipates a net loss in the first quarter of 2026 due to revenue expectations and higher operating expenses [23] Company Strategy and Development Direction - The company is focused on developing a new CPT code for the Inspire V procedure, as the current -52 modifier is not seen as a long-term solution [31][82] - The company plans to enhance patient access to Inspire therapy by training advanced practice providers and certifying additional surgeons [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the Inspire V system's effectiveness and the ability to work with payers to minimize reimbursement reductions [104] - The company is addressing challenges related to the WISeR program, which requires prior authorizations for Medicare cases in six pilot states [15][37] Other Important Information - The company completed $50 million of share repurchases in the fourth quarter, bringing the full year total to $175 million [19] - The company is nearing completion of manufacturing the Inspire IV systems but has sufficient inventory for centers that may choose to continue using them [9] Q&A Session Summary Question: Clarity on physician fee with Gen 5 using the 82 code and -52 modifier - Management indicated that existing policies must be followed and that they are working with MACs and commercial payers to drive consistency in reimbursement [28][29] Question: Pathway forward for Gen 5 and pursuing a dedicated code - Management confirmed they are pursuing a new CPT code and have inventory of Inspire IV available for physicians who wish to continue using it [32] Question: Impact of the WISeR program on revenue guidance - Management clarified that the primary reason for revenue reduction is coding uncertainty, while the WISeR program is causing some disruption [37] Question: Pricing strategy in light of reimbursement changes - Management stated that they expect consistent product pricing going forward, aligning with the current pricing model [60] Question: Clarification on coding and competition - Management emphasized confidence in their technology and the Inspire V system's strong safety profile, while acknowledging some impact from competition [68] Question: Expectations for commercial payers and billing practices - Management noted that commercial payers currently allow billing under 64568, but they expect a transition to 64582 with the -52 modifier over time [72]

Core Insights - The company preannounced its Q4 and full year revenue, indicating continued growth and adoption of the Inspire V system [1] - Initial revenue guidance for 2026 is projected at 10% to 11% growth, consistent with previous indications [1] - Recent reimbursement developments are viewed positively, although initial revenue guidance does not include contributions from these changes [2] Revenue and Guidance - The revenue guidance for 2026 reflects a growth rate of 10% to 11%, aligning with prior earnings call indications [1] - The procedure code 64568 has been associated with the Inspire V since FDA approval in 2014 and was billed for procedures throughout 2025 [2] - A software update on July 1 was crucial for the launch of the Inspire V device [2]

Core Insights - Inspire Medical Systems, Inc. reported an earnings per share (EPS) of 10 cents for Q1 2025, a significant improvement from a loss of 34 cents in the same period last year and better than the Zacks Consensus Estimate of a loss of 23 cents [1] - The company's revenues reached $201.3 million, reflecting a year-over-year increase of 22.7% and surpassing the Zacks Consensus Estimate by 3.2% [1][2] Revenue Growth - Revenue growth was primarily driven by increased market penetration in existing centers, expansion into new territories, and heightened awareness among physicians and patients regarding the Inspire system, although this was partially offset by capacity constraints among ENT surgeons [2] - U.S. revenues amounted to $193.6 million, marking a 24.3% increase year-over-year, while revenues from all other countries totaled $7.7 million, down 6.4% year-over-year [3][4] Margin and Expense Analysis - Gross profit increased by 22.5% to $170.6 million, but the gross margin contracted by 16 basis points to 84.7% [5] - Selling, general, and administrative expenses rose by 14.9% year-over-year to $144.3 million, while research and development expenses decreased by 3.6% to $27.8 million [5] Financial Position - As of the end of Q1 2025, the company had cash and cash equivalents of $369.2 million, down from $445.5 million at the end of 2024 [7] - Net cash used in operating activities was $6.7 million, compared to net cash provided of $8.9 million in the previous year [7] Outlook - Inspire Medical has reiterated its revenue outlook for 2025, projecting revenues between $940 million and $955 million, which represents a growth of 17-19% from 2024 levels [8] - The company has raised its EPS guidance for 2025 to a range of $2.20 to $2.30, up from the previous outlook of $2.10 to $2.20 [8] Market Performance - Shares of Inspire Medical gained nearly 0.8% in after-hours trading following the earnings announcement [2] - Management indicated that the company is on track for a full launch of the Inspire V system in the U.S. and expects mid to high single-digit sequential revenue growth in Q2 2025 [10] Challenges - The decline in revenues from all other countries and the contraction in gross margin due to rising product costs were noted as disappointing factors [11]